Meropenem is an antibiotic of the carbapenem class, intended for parenteral use, relatively resistant to human dehydropeptidase-1 (DHP-1), and does not require additional administration of a DHP-1 inhibitor. Meropenem has a bactericidal effect by affecting the synthesis of the bacterial cell wall. The high bactericidal activity of meropenem against a wide range of aerobic and anaerobic bacteria is explained by meropenem's high ability to penetrate the bacterial cell wall, high stability to most β-lactamases, and significant affinity to various penicillin-binding proteins (PSBs). Minimum bactericidal concentrations (MBCS) are usually the same as minimum inhibitory concentrations (MICS). For 76% of the bacterial species tested, the MBQ/MIC ratio was 2 or less.

Meropenem is indicated for the treatment of the following infectious and inflammatory diseases in children (older than 3 months) and adults caused by one or more pathogens sensitive to meropenem:

• pneumonia, including nosocomial pneumonia;
• urinary tract infections;
• infections of the abdominal cavity;
• infectious and inflammatory diseases of the pelvic organs, such as endometritis;
• infections of the skin and its structures;
• meningitis;
• septicemia.

Empirical therapy of adult patients with suspected infection with symptoms of febrile neutropenia in monotherapy or in combination with antiviral or antifungal drugs.

The use of meropenem intravenously was effective for the treatment of cystic fibrosis and chronic lower respiratory tract infections both in monotherapy and in combination with other antibacterial drugs. Microbial eradication has not always been confirmed.

Relative overdose is possible in patients with renal insufficiency if no dose adjustment has been performed (see section "Dosage and administration").

Symptoms: increased dose-dependent side effects; manifest mainly in the form of disorders of the central nervous system (confusion, dizziness, impaired consciousness and seizures of the type of epileptic seizures).

Treatment: symptomatic. With normal renal function, the drug is rapidly excreted by the kidneys; with renal insufficiency, meropenem and its metabolite are eliminated from the body by hemodialysis.

In general, meropenem is well tolerated. In rare cases, side effects led to the cancellation of therapy. Serious adverse reactions are rare.

Hypersensitivity to meropenem, to excipients or other drugs of the carbapenem group in the anamnesis. Severe hypersensitivity (anaphylactic reactions, severe skin reactions) to any antibacterial agent with a beta-lactam structure (i.e. to penicillins or cephalosporins). Children under 3 months of age.

Probenecid competes with meropenem for active tubular secretion and, thus, inhibits the renal excretion of meropenem, causing an increase in its half-life and plasma concentration. Since the effectiveness and duration of action of meropenem administered without probenecid are adequate, their combined administration is not recommended.

The possible effect of meropenem on the degree of binding of other drugs to plasma proteins or on their metabolism has not been studied. Given the low binding of meropenem to plasma proteins (about 2%), interactions with other drugs based on the mechanism of displacement from binding to plasma proteins are not expected.

The owner of the registration certificate:
PROMOMED RUS LLC, Russia. 2/2 Pochtovaya str., building 1, room I, Moscow, 105005. 2.
Manufacturer: JSC Biochemist, Russia. Legal address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia.
Production site address: 15A Vasenko St., Saransk, 430030, Republic of Mordovia. Tel.: (8342) 38-03-68 E-mail: biohimic@biohimic.ruwww.biohimic.ru
The organization that accepts consumer claims:
PROMOMED RUS LLC, Russia.
13 Mira Ave., building 1, Moscow, 129090.
Tel.: 8-800-777-86-04 (free of charge), 8-495-640-25-28.
E-mail: reception@promo-med.ru

In a place protected from light at a temperature not exceeding 25 ° C. Keep out of reach of children.

4 years old. Do not use after the expiration date.